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Statistical Evaluation of Evidence for Clonal
Allelic Alterations in array-CGH Experiments
Colin B. Begg, Kevin Eng, Adam Olshen, and E S. Venkatraman

Abstract

In recent years numerous investigators have conducted genetic studies of pairs
of tumor specimens from the same patient to determine whether the tumors share
a clonal origin. These studies have the potential to be of considerable clinical
significance, especially in clinical settings where the distinction of a new primary
cancer and metastatic spread of a previous cancer would lead to radically different
indications for treatment. Studies of clonality have typically involved comparison
of the patterns of somatic mutations in the tumors at candidate genetic loci to see
if the patterns are sufficiently similar to indicate a clonal origin. More recently,
some investigators have explored the use of array CGH for this purpose. Standard
clustering approaches have been used to analyze the data, but these existing statistical methods are not suited to this problem due to the paired nature of the data,
and the fact that there exists no “gold standard” diagnosis to provide a definitive
determination of which pairs are clonal and which pairs are of independent origin.
In this article we propose a new statistical method that focuses on the individual
allelic gains or losses that have been identified in both tumors, and a statistical test
is developed that assesses the degree of matching of the locations of the markers
that indicate the endpoints of the allelic change. The validity and statistical power
of the test is evaluated, and it is shown to be a promising approach for establishing
clonality in tumor samples.
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SUMMARY
In recent years numerous investigators have conducted genetic studies of pairs of tumor
specimens from the same patient to determine whether the tumors share a clonal origin.
These studies have the potential to be of considerable clinical significance, especially in
clinical settings where the distinction of a new primary cancer and metastatic spread of a
previous cancer would lead to radically different indications for treatment. Studies of
clonality have typically involved comparison of the patterns of somatic mutations in the
tumors at candidate genetic loci to see if the patterns are sufficiently similar to indicate a
clonal origin. More recently, some investigators have explored the use of array CGH for
this purpose. Standard clustering approaches have been used to analyze the data, but
these existing statistical methods are not suited to this problem due to the paired nature of
the data, and the fact that there exists no “gold standard” diagnosis to provide a definitive
determination of which pairs are clonal and which pairs are of independent origin. In this
article we propose a new statistical method that focuses on the individual allelic gains or
losses that have been identified in both tumors, and a statistical test is developed that
assesses the degree of matching of the locations of the markers that indicate the endpoints
of the allelic change. The validity and statistical power of the test is evaluated, and it is
shown to be a promising approach for establishing clonality in tumor samples.
Keywords: clonality; array CGH; permutation test.
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1. INTRODUCTION
Clinical investigators frequently conduct experiments to determine whether
tumors share a clonal origin. That is, one wishes to determine if the tumors are derived
from the same “clonal” cell. In addition to informing the interpretation of experiments
about the mechanistic development of cancers, comparisons of samples of cells from
pairs of tumors from the perspective of clonality can have important clinical implications.
For example, a patient treated effectively for a localized primary head and neck cancer
may at a later date present with a solitary lung nodule. If the nodule is a localized second
primary lung cancer it can be treated effectively by surgery, though lung surgery is risky
and very invasive. On the other hand, if the tumor is a metastasis from the head/neck
primary, the prognosis of the patient is necessarily poor, as the cancer will almost
certainly have also metastasized to other parts of the body (even though these other
metastases may not yet be detectable). In this case invasive surgery would impose
needless risks and morbidity on a patient who will have relatively little time left to live.
Currently, pathologists make this call on the basis of histopathologic
characteristics, but this is not a definitive strategy. Recently, many investigators have
begun to study the issue by using molecular profiling of the tumors. For example,
investigators studying lung cancer have used microsatellite markers to distinguish
microsatellite instability (Huang 2001, Dacic 2005, Geurts 2005, Leong 1998, Shin 2001)
and several investigators have also used mutational analysis of the important cancer
genes p53 and/or K-ras (Hiroshima 1998, Holst 1998, Lau 1997, Shimizu 2000, Shin
2001, Murase 2003, Matsuzoe 1999, Sozzi 1995, van Rens 2002). Similar studies have
been conducted to distinguish contralateral breast cancers fron metastases, and in other
cancer sites (Imyanitov 2002, Regitnig 2004, Kollias 2000, Janschek 2001, Tse 2003,
Schlechter 2004, Stenmark-Askmalm 2001, Chunder 2004). These studies have
evaluated clonality in a range of clinical settings, including the comparison of
synchronous or metachronous multiple primaries, comparisons of primaries with
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metastatic tumors, and studies of multiple potential clones within tumors that harbor
multiple histologies. By studying the mutational pattern, one can establish a genetic
fingerprint of the tumor. When the mutational profiles of two apparently independent
primary tumors from the same patient are compared, it is possible in principle to see
whether these genetic fingerprints are sufficiently similar that we can determine with
confidence that they share a clonal origin, i.e. the second primary is really a metastasis
from the first primary.
The comparison of mutational profiles of tumors to determine clonality is a
challenging statistical problem, and a number of authors have proposed techniques for
this purpose. The fundamental goal is to examine the profiles of the two tumors to see
whether the evidence favors a clonal versus an independent origin for the tumors. In
earlier work we examined candidate statistical tests for this purpose, based on the setting
in which the frequencies of mutational events (usually LOH) at candidate loci are
assessed for correlation, with a view to determining if the correlation exceeds the level
that is plausible on the basis of chance (Begg et al. 2006). These tests take advantage both
of the information in the correlation of mutational events and the extent to which
common mutations at the same locus occur on the same parental allele. The tests have
been shown to be reasonably powerful provided that information is available from a
considerable number of candidate genetic loci that experience mutational events with
reasonably high frequency in the cancer under study, and that the signal is relatively
strong, i.e. the preponderance of the mutations occur in the clonal phase of development.
Other authors have approached this problem in different ways. For example Sieben et al.
(2003) and Brinkmann et al. (2004) both construct likelihood ratios to distinguish the
evidence favoring the two hypotheses, though the construction is somewhat different in
each case. A different approach was advocated in earlier work by Kuukasjarvi et al.
(1997), who proposed a measure of clonal relatedness based on the frequency of
occurrence of concordant mutations in the tumors, and this measure has been used by
other authors such as Jiang et al. (2005) and Goldstein et al. (2005a,b).
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The preceding methods are all based on the setting in which we observe mutations
in a pre-specified set of candidate markers in each tumor, and we evaluate the collective
concordance of these markers. Since the common somatic mutations in tumors are
frequently losses or gains of segments of DNA, the issue of clonality can be studied for
the entire genome using array technology, specifically array comparative genomic
hybridization (ACGH) (Pinkel et al. 1998). By scanning the entire genome for copy
number changes this technology has the potential to provide a more comprehensive
comparison of the two tumors, and to provide insights beyond those available from
studies of LOH at individual markers. In particular, ACGH can detect both copy number
gains and losses, and it can pinpoint the places in the genome where these gains and
losses begin and end, although it does not distinguish the specific allele on which the loss
or gain occurs. Despite the potential precision with which a specific allelic gain or loss is
determined, statistical methods used in this context have employed strategies that simply
count mutational events, as in the methods described above for studies based on
candidate loci. For example, investigators have used the data from the arrays to define the
presence or absence of, say, LOH at the level of the chromosome arm (Jiang et al. 2005)
or chromosome band (Teixeira et al. 2004) in order to define the unit of analysis for the
use of statistical tests or clustering algorithms, or for the computation of the clonal
relatedness index.
Our strategy in this article is to take advantage of the aspect of ACGH data that
distinguishes the nature of the information from that obtained in studies involving
candidate genetic loci, namely the granularity of the information regarding the allelic
gains and losses. This feature of the data provides the ability to pinpoint the start and stop
regions of these allelic changes, with a view to determining an exact match between the
mutations on the two tumors. In so doing, our method offers the potential to establish
clonality on the basis of a single allelic gain or loss simply on the basis of the closeness
of the match, regardless of the possible absence of concordance of bystander somatic
events that may have occurred after the two tumors developed as separate clones. Even
though a clonal allelic gain or loss is necessarily identical on both tumors, noise in the
measurement of the CGH markers results in statistical uncertainty regarding the precise
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start and stop points of the allelic change. The goal of our approach is to see if the
estimated start and stop points of allelic events on the two tumors that appear to be
possibly clonal are sufficiently close that events of such a degree of similarity are
unlikely to have occurred by chance. The construction of a valid statistical test for this
purpose is challenging for several reasons, including the fact that gains or losses of
independent origin are likely to be correlated, since their locations on the genome do not
occur independently.

2. METHODS
Array comparative genomic hybridization is a technique for determining allelic
copy number changes across the entire genome. Samples of tumor tissue and normal
tissue are differentially labeled and co-hybridized to a slide containing genomic markers
with a view to determining regions of allelic loss or gain in the tumor. Several array
techniques have been developed to increase resolution in order to permit identification of
relatively small allelic changes (Pinkel and Albertson 2005). The result is a linear map of
marker values which represents the copy number in the tumor at sequential locations
across the genome.[The measurements are relative but they reflect the absolute copy
number of the tumor.] These marker values are, of course, subject to random variation,
and so the determination of regions of gain or loss requires statistical analysis, and
several techniques for this purpose have been developed (reviewed in Lai et al. 2005).
Our goal in this article is to compare the ACGH profiles from two tumors in the
same patient, with a view to determining whether the tumors arose independently, or
were derived from a single clonal cell that experienced one or more of the observed
allelic changes. If there are “clonal” mutations in the two tumors then these are
necessarily identical. Thus the estimated regions of gain or loss must be very similar in
the two tumors, though estimates of the precise markers at which the regions of gain or
loss begin and end will not necessarily be identical, due to random fluctuations in the
marker values, and the resulting imprecision of the methods in identifying the regions of
gain or loss.
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An example of data from two tumors from the same patient is provided in Figure
1. The horizontal lines show estimated regions of constant copy number, and
discontinuities within chromosomal arms indicate positions of presumed allelic loss or
gain. The key question is whether one (or more) of the somatic events can be
convincingly demonstrated to be clonal, on the basis of the exactness of the match. The
arrows in the diagram point to changes that look plausibly similar at first glance, and our
test is designed to examine these plausible matches individually. In other words we
reduce the problem to an evaluation of the likelihood of a match for the specific
concordant allelic changes observed in both tumors. Our method addresses whether any
of these changes are close enough to convince us that the tumor is of clonal origin.
Regions of gain or loss are evaluated within chromosome arms, and these
frequently involve the gain or loss of an allele across the entire chromosome arm. Other
patterns include partial arm alterations, simple alterations and complex alterations. A
simple alteration is one in which a single allelic gain or loss occurs within the
chromosome arm. Partial arm alterations are, in essence, simple alterations in which one
of the two endpoints occurs at a boundary. A complex pattern of alterations involves
more than one gain or loss (see Figure 2). As background for this article we examined
high-resolution ACGH data from a series of 38 patients with diffuse large B-cell
lymphoma diagnosed between 1984 and 1998 (Chen et al. 2006). Among all of the
chromosomal arms examined, changes were identified in 18%. Excluding whole arm
changes, the preponderance of alterations were either partial arm (46%) or simple (43%)
changes. Since the presence of a whole arm alteration is relatively common it is not
improbable that the same alteration will occur by chance on both tumors. Consequently,
the occurrence of a concordant whole arm gain or loss on the same chromosomal arm on
both tumors will not provide strong enough evidence on its own to establish a clonal
origin for the tumors, though it will be relevant in aggregating the evidence from the
entire genome. Most of the remaining types of mutational events are either partial arm
alterations or simple alterations. We focus in this article on the challenge of comparing
concordant simple or partial alterations that occur on the same chromosome arm of the
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two tumors. By “concordant”, we mean that either both changes are gains or both are
losses, and that each one represents a statistically significant allelic change on the basis a
statistical test for detecting allelic change. We develop a new statistical test for
comparing the estimated start and stop markers in the two tumors. We regard the
resulting test as being the building block for interrogating the entire pattern of mutations
on the two tumors.
Our general strategy is conceptually straightforward. After defining notation in
the next section, we propose a test statistic that represents the “closeness” of the observed
allelic changes on the two tumors. We then outline an approach to determining a
reference distribution for this statistic under the null hypothesis that the two mutations
occurred independently. This is a challenging task for several reasons that are discussed
in detail. Later we examine the validity and power of the test using simulations, and
apply it to data from various patients.
2.1 Notation and Test Statistic

Let xuk represent the measurement of the u th marker of the k th tumor,
where u = 1,.., n, and k = 1,2. Consider the setting in which there is a concordant gain (or

loss) on the two tumors. Let the copy number change begin at marker ik and end at
marker j k for the k th tumor. That is, markers ik through j k , inclusive, represent the
markers of allelic gain (or loss). If the tumors are clonal then i1 = i2 and j1 = j 2 , and this
represents the alternative (clonal) hypothesis in our formulation. The null hypothesis is
that the regions of gain or loss have arisen independently and consequently that the
endpoints of the allelic change are very unlikely to be identical. [Note: we recognize that
an exact match could occur by chance, though this is highly improbable at the levels of
granularity of the arrays in which we are interested.]
The endpoints need to be estimated using an algorithm for detecting regions of
allelic change. In our simulations we use the CBS (circular binary segmentation)
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algorithm (Olshen et al., 2004), although in principle any similar method could be used.
The CBS algorithm obtains estimates of the endpoints, denoted iˆk and ĵ k , by maximizing
the mean difference between the markers in the hypothesized region of gain or loss and
the remaining markers. In fact, the CBS algorithm chooses iˆk and ĵ k to maximize z ijk
where

z ijk

⎛ 1
⎞
1
⎟⎟
= ⎜⎜
+
⎝ j − i +1 n − j + i −1⎠

−1 / 2

⎛ S jk − S i −1,k S nk − S jk + S i −1,k
⎜⎜
−
1
j
i
n − j + i −1
−
+
⎝

⎞
⎟⎟,
⎠

l

and where S lk = ∑ xuk . [Note that in the Olshen et al. (2004) manscript the region of
u =1

change is defined as ik + 1 through j k , rather than ik through j k . ] A permutation
algorithm is used to determine whether the detected change is statistically significant. In
the published version of the CBS algorithm (Olshen et al. 2004) this process continues
until all statistically significant change points are detected. In the strategy for this article
we limit the CBS algorithm to the initial step for detecting the single, most highly
significant allelic change. In our testing strategy for clonality, we start with the
assumption that the CBS algorithm has detected concordant allelic changes on each
tumor, both of which are statistically significant. The changes are concordant if δ 1 = δ 2 ,
where δ k = sign(max[ z ijk ]) . Based on these conditions our test statistic is defined as
t = iˆ1 − iˆ2 + ˆj1 − ˆj 2 .

(2.1)

Thus small values of t are indicative of a possible clonal mutation.
2.2 Reference Distribution
Since our test is based on the condition that two concordant allelic changes are
present, our reference distribution under the null hypothesis of independence must also be
based on this assumption, i.e., we assume that there exists allelic changes on both tumors
that have arisen independently, and that either both represent gains or both represent
losses. The reference distribution for t should then reflect the distribution of t when
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(concordant) independent allelic gains or losses are generated on each tumor on the same
chromosomal arm. The construction of the reference distribution is a challenging task for
the following reasons.
The fact that the two sets of data being compared are required to have statistically
significant observed allelic changes makes a direct permutation of the data invalid since
the distribution of the markers is non-exchangeable (the gained or lost region has a
different mean than the region of normal copy number). A plausible assumption of
exchangeability of the marker values can be induced by subtracting the true means from
the observed data. That is, the reference distribution can be generated by permuting the
residuals. However, this requires knowledge of the location of the changes and the
corresponding means. In our approach we use the estimated locations and means instead.
Specifically, let θ k denote the mean value for markers representing normal copy number
for the k th tumor, and let μ k denote the mean marker value in the region of allelic
change. We estimate these using their sample means as follows,
ˆ

jk
1
μ̂ k =
xuk
ˆj k − iˆk + 1 u∑
=iˆk

θˆk =

n
⎡ iˆk −1
⎤
1
+
x
xuk ⎥ .
⎢
∑
∑
uk
n − ˆj k + iˆk − 1 ⎣ u =1
u = ˆjk +1
⎦

These are used to obtain residuals for each of the marker values:-

ruk = xuk − θˆk for u < iˆk or u > ˆj k
ruk = xuk − μ̂ k for iˆk < u < ˆj k .
In order to obtain resampled data corresponding to two tumors with concordant allelic
changes, the permuted residuals are added back to new mean functions that are
regenerated for each permutation.
Generation of these mean functions is complicated by the fact that allelic changes
will not occur at random in tumors. While chromosomal breakpoints may occur
randomly in cells, the alteration is more likely to be retained if it contains a gene or genes
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for which there is an advantage to having an abnormal number of copies, such as an
oncogene or a tumor suppressor gene. This results in selection and clonal expansion of
cells harboring specific genomic alterations. To address this phenomenon we first
generate a location for a hypothetical mutational hotspot, which we presume to be located
where the observed regions of allelic loss or gain on the two tumors overlap. We
randomly generate new regions of allelic change for the two tumors, restricted to the set
of changes that overlap the hotspot. We use the aggregate data from the two tumors to
estimate the mean values for the normal and allelic change markers to increase the
stability of the process.
Since the samples being compared have concordant allelic changes that have been
detected as statistically significant individually, the reference distribution should also be
based on samples with statistically significant changes. Hence, we use the same algorithm
on the generated data for each tumor as the one used for the original data (CBS in our
case) to estimate the start and stop points for the allelic changes, and to test their
statistical significance. If both are significant at the same α level as the original sample
and the changes are concordant, then the data set is considered to be “admissible”, and
the estimated endpoints are used to calculate the reference test statistic. This process is
then repeated a large number of times to establish the reference distribution for the
statistic t in (2.1).
The operating characteristics of this procedure depend on the signal to noise ratio
as well as the properties of the procedure used for the estimation of the locations of the
change-points and the means of the marker values. The ability to detect a change is a
function of the signal-to-noise ratio. A lower signal-to-noise ratio results in a larger
proportion of false positives among the detected changes. It also affects the test for
clonality by increasing the frequency of inadmissible permutations. Also, the CBS
algorithm chooses the maximum value of the CBS test statistic from among all of the
possible combinations of start and stop markers for the allelic change. Since for any two
pairs of start and stop markers the correlation between these statistics increases with the
number of overlapping markers, the CBS algorithm tends to select smaller intervals in
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preference to larger intervals when there is no real allelic change, i.e. when there is a
false positive change. This preference for shorter intervals is high when the signal to
noise ratio is relatively low since the preponderance of statistically significant intervals
are false positives. It poses a further problem for choosing the location of the mutational
hotspot since the intervals of allelic change on the two tumors are less likely to overlap.
The following algorithm for generating the reference distribution is constructed in
recognition of these issues. An asterisk denotes terms representing the reference
distribution:(1) Generate the location of the mutational hotspot h * , where h * is selected
uniformly from the common interval, i.e. the interval between max (iˆ1 , iˆ2 ) and min

( ˆj1 , ˆj 2 ). [For simplicity we assume throughout that the hotspot occurs at a marker
value, and define U (i, j ) to represent uniform sampling of the markers between i
and j , inclusive.] If the intervals do not overlap then h * should be chosen
randomly from the interval between the estimated intervals, i.e. if the second
interval is higher than the first, then choose h * randomly between ĵ1 and iˆ2 , and
vice versa. [The goal here is to accommodate two very short intervals that are
close to each other but do not overlap.]
(2) Generate the “true” endpoints of the allelic changes in the reference data set:
i1* and i2* sampled from U(1, h * ) and j1* and j 2* sampled from U( h * ,n).

(3) Obtain {ruk* }, a permuted set of the residuals {ruk }, permuted separately for each
tumor.
*
(4) Create the permuted marker values {xuk
} using
*
xuk
= θˆ + ruk* if u < ik* or u > j k*

= μˆ + ruk* if ik* ≤ u ≤ j k* ,

where
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(n − ˆj1 + iˆ1 − 1)θˆ1 + (n − ˆj 2 + iˆ2 − 1)θˆ2
(n − ˆj1 + iˆ1 − 1) + (n − ˆj 2 + iˆ2 − 1)
( ˆj − iˆ + 1) μˆ 1 + ( ˆj 2 − iˆ2 + 1) μˆ 2
μˆ = 1 1
.
( ˆj1 − iˆ1 + 1) + ( ˆj 2 − iˆ2 + 1)

θˆ =

(5) Use the CBS algorithm on the new dataset for each tumor to obtain the estimated
endpoints of the regions of allelic change, denoted (iˆ1* , ˆj1* ) and (iˆ2* , ˆj 2* ). Include
the generated data as admissible only if both allelic changes are statistically
significant at the 5% level, and if they are concordant, i.e. if δ 1* = δ 2* where

δ 1* = sign( μˆ 1* − θˆ1* ) and δ 2* = sign( μˆ 2* − θˆ2* ), and where μˆ k* and θˆk* are the
respective means of the markers in the altered and normal subsets of the data,
respectively.
(6) Calculate the reference value for the test statistic using
t * = iˆ1* − iˆ2* + ˆj1* − ˆj 2* .

(7) Repeat the process a large number of times to obtain the distribution of t * .
The p-value for the resulting test is obtained by determining the number of admissible
permutations N t such that t * ≤ t. The p-value is then N t / N , where N is the total
number of admissible permutations.
2.3 Validity and Power of the Test Statistic
We have conducted a series of simulations to examine the properties of the test.
The first consideration is validity. Is the size of the test less than or equal to the nominal
value under the null hypothesis? Recall from the previous section that our testing strategy
was designed to offset three validity challenges. The first is that allelic changes do not
occur at random, but instead span sites where changes confer a selective advantage. Our
test was constructed under the assumption that there exists a mutational hotspot in the
region common to the two allelic changes being compared, and the reference distribution
is consequently restricted to data configurations in which the admissible intervals of
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allelic change must span the hotspot. This aspect of the test cannot be evaluated
confidently from a theoretical basis. It is simply an assumption. Logic suggests that this
restriction should make the test more conservative, i.e. make the p-values larger, since we
are eliminating many potential permutations in all of which at least one of the mutations
does not span the hotspot. These permutations should, on average, have test statistics that
are larger (i.e. less “close”) than the test statistics of admissible permutations. Later, in
Section 2.4, we address this assumption indirectly in an empirical evaluation of the size
of the test using data from tumors from different patients.
The remaining two validity challenges, the dependence on the CBS algorithm to
identify the allelic changes given its preference for selecting small intervals, and the
dependence of the test on an estimated signal to noise ratio, are evaluated in the following
manner. Data for each marker were assumed to be normally distributed from distributions
with a predefined signal strength. That is we specified the mean value for markers at
normal copy number, denoted θ , and the mean in the region of allelic change, denoted

μ , with common variance σ 2 . These were chosen to specify the signal strength,
represented by μ − θ / σ , and one of the means was set to 0 and the variance set to 1
without loss of generality. For each simulation we first select a true mutational hotspot at
marker h. This was randomly generated from the n markers for each data set. We then
generated a data set as follows. First the “true” endpoints of the allelic changes were
randomly generated, i1 and i2 as U(1, h ), and j1 and j 2 as U( h, n ). Observed marker
values were generated as normal random variables. That is, xuk was generated as
N( θ k , σ 2 ) for u < ik or u > j k and as N( μ k , σ 2 ) for ik ≤ u ≤ j k . The CBS algorithm was
used on these data to estimate the endpoints, denoted iˆ1 , ˆj1 , iˆ2 , ˆj 2 , and the test statistic t
was calculated using (2.1).
Following the procedure outlined in Section 2.2, the p-value was calculated with
1000 replicates from the reference distribution. The entire process was then repeated
1000 times and the relative frequency with which the test was significant is reported as
the test size. Thus the simulation standard error is about ± 0.02 in the estimated test size.
12
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The embedded CBS algorithm uses a default of 10,000 permutations to compute its pvalue at its default significance level of 0.01. In our case we are using α=0.05, and so we
reduced the number of CBS replicates to 2000 for the original statistic t and to 400 for
the permuted statistic t * to minimize the computational burden. Since the simulation
relies on the ability of the CBS algorithm to uncover significant intervals, when signal
strength or the number of markers is small it may be difficult to create enough significant,
concordant draws from the reference distribution. The procedure is allowed as many
attempts as necessary to complete the 1000 replicates required, and likewise it is allowed
as many attempts as necessary to generate a significant, concordant data set. The results
are presented in Table 1 for signal strengths ranging from 0.5 to 3 standard deviations,
and for numbers of markers ranging from 65 to 141. The results show that in general the
test is valid.
For the bacterial artificial chromosome (BAC) arrays we have been using the
numbers of markers per chromosome arm ranged from 20 to 141. However, in our
simulations, for arms with relatively few markers the CBS algorithm rarely detected any
significant alterations, and so our test has very low power in this setting. These data are
from the Spectral Genomics SpectralChip 2600, an array with 2621 markers. The
numbers of markers in the simulations are representative of the counts from the
chromosome arms on that array. The SpectralChip is typical in size for a modern BAC
array. Oligonucleotide arrays consisting of thousands of markers per arm are also in use
(Pinkel and Albertson, 2005).
We evaluated the power of the test to detect clonal allelic changes in a similar
manner with the exception that the underlying “true” allelic change was assumed to be
identical for both tumor 1 and tumor 2. That is we first randomly generated the hotspot at
marker h. Then we randomly generated the endpoints of the allelic change below and
above the hotspot, i from U(1, h ), and j from U( h, n ), and set i1 = i2 = i and
j1 = j 2 = j. The simulations were then generated as outlined above. We also explored

whether the location and the length of the allelic change have an impact on power, by
repeatedly generating data for allelic changes of a specific length and position. Thus, for
13
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example, we selected a change that began at marker 5 and ended at marker 10 by
generating data from this configuration repeatedly and examining the relative frequency
with which the test was significant. The results of these power calculations are in Table 2.
The first row represents simulations in which lengths and locations of the true
common signals varied randomly. The other rows represent power to detect a change
with a specific length and location. Several conclusions may be drawn from the results.
First, the granularity of the array is important, i.e. a chromosome arm with many markers
is more likely to detect a clonal change than an arm with relatively few markers (for a
given signal strength). Second, not surprisingly, the signal strength is important, with
higher signal strength leading to greater statistical power. The results also suggest that
short allelic changes may have somewhat less power than larger allelic changes. This can
be explained as follows. For a given value of μ the non-centrality parameter for
identifying an allelic change by the CBS algorithm is parabolic with respect to the width
of the allelic change, with a maximum when the true allelic change is exactly half of the
width of the chromosome arm. Consequently smaller true intervals lead to a greater
relative frequency of CBS false positives which in turn introduce more noise into the
comparison of the observed allelic changes in the two tumors when the true change is
clonal. In general, arrays with 100 or more markers appear to have high power to detect a
clonal change if the difference in means is 2 standard deviations or greater.
The power we can expect from these experiments clearly depends heavily on the
signal strength. We have examined the signal strengths empirically in the series of 38
lymphoma patients. For each chromosomal arm with a detected simple allelic change we
calculated the standardized mean difference between the markers in the region of allelic
change and the remaining markers, and these estimates are plotted in Figure 3, based on a
sample size of 111 observed allelic changes. The results suggest that the signal strength is
typically quite strong, averaging about 2 standard deviations.
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2.4 Data Analyses
The preceding simulated calculations of size and power are compromised by the fact that
they are embedded with some key assumptions, notably the assumption that observed
concordant allelic changes necessarily span a mutational hotspot, and the assumption that
marker values have normally distributed errors. To examine the validity of the test from
an empirical perspective that does not depend on these assumptions we have reanalyzed
the dataset of 38 tumors from patients with diffuse large B-cell lymphoma (Chen et al.
2006). For each chromosomal arm (excluding the X chromosome) we compared the
profiles for every pair of patients, and performed the test for any observed concordant
changes. Since the tumors came from different patients none of the observed concordant
changes are clonal, by definition. Thus, the proportion of tests that are significant should
approximate the nominal 5% level. In this exercise we identified a total of 745 pairs of
changes that were individually detected as significant by the CBS algorithm on the same
chromosome arm. These yielded 42 statistically significant comparisons using our
algorithm, for an empirical test size of 0.056 (42/745).
We also have access to an additional set of matched ACGH results from two
tumors in each of two patients. Both of these examples are of tumors that are
presumptively clonal. The tumors from the first patient are both mediastinal metastases
(the “mediastinal” patient). The tumors of the other patient are of a primary testis cancer,
matched with a lymph node metastasis (the “testis” patient). The complete arrays for the
mediastinal patient are displayed in Figure 1. Visual examination of the arrays from the
two tumors indicates that there are plausibly clonal concordant changes on arms 2, 5, 6,
7, 24, 34 and 39. The test statistics for these 7 comparisons are 1, 0, 9, 2, 1, 3, and 0,
respectively, based on numbers of markers 94, 70, 93, 46, 84, 43 and 35. These
correspond to, respectively, p-values of 0.010, 0.010, 0.095, 0.035, 0.005, 0.135, and
0.005. The collective levels of significance of these changes provide strong evidence of
clonality in that 5 of the changes are nominally significant, and four are quite highly
significant. Data from these arms are displayed with greater magnification in Figure 4,
along with reference distributions for the test statistics. The testis patient presents less
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visual evidence for clonality. The array for the first tumor detects only two significant
allelic changes, on arms 4 and 16. For the second tumor, changes are detected on arms 4,
20, 22, 34 and 38. Thus arm 4 is the only place where a possible clonal event may have
occurred. This arm has 141 markers, the test statistic for the comparison is 3 and the
corresponding p-value is 0.015.

3. DISCUSSION
The results demonstrate that the proposed test can deliver quite high power for
establishing the clonality of observed concordant allelic changes on the two tumors.
However, to achieve high power, in excess of 90%, the data from the relevant
chromosomal arm must be sufficiently granular (100 markers or greater) and the signal
strength must be sufficiently high (around 2 standard deviations or greater). In the
absence of these conditions the CBS algorithm is too imprecise at determining the
beginning and the end of the regions of allelic gain or loss to establish clonality with
sufficient confidence. However, as array technology develops, both the granularity and
the signal strength are likely to increase, promising greater resolution accuracy for this
method.
An intangible feature of the method in practice will be the manner in which
investigators choose the allelic changes that deserve to be tested for clonality.
Investigators are only likely to be inclined to perform the test for allelic changes that look
close enough to be clonal. Consequently there is an ill-defined multiple testing aspect to
the process of evaluating the totality of available data from the arrays. In general, arrays
that exhibit lots of allelic changes are more likely to exhibit some changes that “look”
clonal, simply by chance, and so the false positive rate must be higher in this case, though
it is not obvious how to formulate this issue precisely.
In practice, the ultimate aim is to determine if the tumors are clonal, and this
should involve assessing the evidence for and against clonality across the entire genome.
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This might involve conducting tests for all of the simple or partial allelic changes that are
plausibly clonal upon inspection, but the issue of how to combine this evidence into a
unitary decision rule is challenging. For example, suppose that we test three locations
where allelic changes look similar on the two tumors. Does the presence of three
statistically significant tests with p-values only modestly lower than the nominal 5% level
provide more convincing evidence for clonality than, say, a result in which one of the
tests is very highly significant but the other two are non-significant? In general, if there
are many somatic changes that are clearly independent should this diminish our
confidence in the clonal hypothesis in the face of a single, highly significant match? This
question rests on the issue of how common it is to find clonal tumors that exhibit lots of
bystander (independent) allelic changes. We feel that these questions are difficult to
address at present, without access to much more data on the patterns of mutations in
clonal and independent pairs of tumors. The proposed test is offered as a building block
for interrogating the full genomic evidence available from an individual patient, and as a
framework for future research on the most appropriate statistical techniques for
addressing this important problem.
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Figure 1. Log ratio measurements from ACGH of two different metastases from the
“mediastinal patient.” The horizontal lines show CBS estimated segments, and the
vertical lines separate chromosomal arms (1 to 46 representing chromosomes 1-22 and
chromosome X). The arrows indicate chromosome arms where plausible clonal changes
may have occurred.
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Figure 2. Data examples of alteration patterns. The dotted line indicates normal copy
number. The frequencies of these patterns were determined empirically from a sample of
38 independent patients with cancer.
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Figure 3. Histogram of estimated signal strengths derived empirically from 38 patients
with lymphoma.

24
Hosted by The Berkeley Electronic Press

25
http://biostats.bepress.com/mskccbiostat/paper13

Figure 4. Details of chromosomal arms and corresponding clonality test permutation
reference distributions for the concordant changes in the “mediastinal” patient. On the
histogram, the vertical dotted line denotes the observed test statistic, and the proportion
equal to and to the left of the line determines the p-value.
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Table 1. Simulated size of the clonality test measured as the proportion of significant

tests (p <=0.05) in 1000 pairs using randomly selected concordant intervals spanning a
common hotspot.
# Markers

Signal Strength (S.D.)
0.5

1.0

2.0

3.0

65

0.02

0.05

0.05

0.06

100

0.04

0.04

0.05

0.06

141

0.05

0.05

0.06

0.05
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Table 2. Simulated power of the clonality test for various signal strengths and
alternatives.
# Markers

65

100

141

Signal Strength

1

2

1

2

1

2

Random

0.29

0.85

0.49

0.94

0.60

0.98

[1,5]

0.31

0.78

0.40

0.87

0.38

0.90

[5,10]

0.27

0.72

0.37

0.80

0.39

0.88

[1,30]

0.38

0.87

0.50

0.95

0.62

0.98

[5,35]

0.23

0.86

0.38

0.93

0.52

0.98

[30,60]

0.30

0.83

0.47

0.97

0.59

0.98
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